CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
Folfox Protocol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03259035
NCT03259035Phase 2Completed
CompareCT.gov

NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

Canadian Cancer Trials Group·interventional·Posted Aug 23, 2017·Updated Apr 9, 2026

In Brief

A Phase 2 clinical trial evaluating Folfox Protocol and Capox for Rectal Cancer. Completed, enrolled 58 participants across 11 sites in 2 countries.

Detailed Summary

The purpose of this study is to find out the effects of chemotherapy followed by less invasive surgery on patients and their early rectal cancer. The approach of this trial will be considered a success if at least 65% of participants are able to keep the rectum.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRectal Cancer
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 23, 2017
Enrollment StartJun 29, 2018
Primary CompletionApr 8, 2024
Study CompletionApr 25, 2024
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 8.9 years ago

Interventions

Folfox Protocoldrug

6 cycles of q2weekly FOLFOX, or

Capoxdrug

4 cycles of q3weekly CAPOX